亚甲蓝光病毒灭活血浆的研究进展*

doi:10.3969/j.issn.1671-2587.2021.02.029

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (2): 268-272.DOI: 10.3969/j.issn.1671-2587.2021.02.029

• 综述 • 上一篇

亚甲蓝光病毒灭活血浆的研究进展^*

黄佳丽, 刘正婷, 陈尚良, 周义文

518100 南方医科大学深圳医院,南方医科大学第三临床医学院

收稿日期:2020-07-05 出版日期:2021-04-20 发布日期:2021-04-19
通讯作者: 陈尚良,男,副主任技师,博士,主要从事临床输血工作,（E-mail）fimmu2000@163.com。共同通信作者：周义文,男,主任技师,博士,主要从事临床检验工作,（E-mail）yiwenzhou21@aliyun.com。
作者简介:黄佳丽（1993-）,女,广东汕头人,在读研究生,主要从事输血学研究,（E-mail）hjlduck@163.com。
基金资助:
*本课题受深圳市科技计划（No.JCYJ20190814110401673）资助

Received:2020-07-05 Online:2021-04-20 Published:2021-04-19

摘要/Abstract

摘要： 随着输血医学的发展,血液安全得到了显著改善,但仍受到新发传染病病原体和未知病原体的威胁。免疫介导的反应是输注血浆最常见的不良反应。血浆输注的两大风险是感染风险和免疫风险。亚甲蓝光化学法是目前我国用于血浆病毒灭活的主要方法之一,能有效灭活大多数脂质包膜病毒。为探讨亚甲蓝光病毒灭活血浆应用的安全性,本文对其灭活病毒的有效性、对凝血因子的影响、输注的不良反应及血浆残余亚甲蓝的安全性作一综述。

关键词: 亚甲蓝, 病毒灭活血浆, 病毒的灭活, 凝血因子, 安全性

中图分类号:

R457.1

黄佳丽, 刘正婷, 陈尚良, 周义文. 亚甲蓝光病毒灭活血浆的研究进展^*[J]. 临床输血与检验, 2021, 23(2): 268-272.

参考文献

[1] LOZANO M,CID J,MÜLLER T H.Plasma treated with methylene blue and light: clinical efficacy and safety profile[J].Transfus Med Rev,2013,27(4):235-240.
[2] NOENS L,VILARIÑO M D,MEGALOU A,et al.International,prospective haemovigilance study on methylene blue-treated plasma[J].Vox Sang,2017,112(4):352-359.
[3] 国家卫生健康委.血站技术操作规程(2019版)[EB/OL].(2019-04-28). http://www.nhc.gov.cn/yzygj/s7658/201905/bdd4f4ccd15c4201bfb6d9e7492d7fab.shtml.
[4] 中华人民共和国国家质量监督检验检疫总局,中国国家标准化管理委员会.全血及成分血质量要求:GB 18469—2012[S].北京:中国标准出版社,2012.
[5] TCHEN S,SULLIVAN J B.Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock[J].J Crit Care,2020,57:148-156.
[6] CICCHETTI A,BERRINO A,CASINI M,et al.Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use[J].Blood Transfus,2016,14(4):287-386.
[7] EICKMANN M,GRAVEMANN U,HANDKE W,et al.Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus,Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light[J].Vox Sang,2020,115(3):146-151.
[8] FADDY H M,FRYK J J,HALL R A,et al.Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light[J].Transfusion,2019,59(7):2223-2227.
[9] EICKMANN M,GRAVEMANN U,HANDKE W,et al.Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light,respectively[J].Transfusion,2018,58(9):2202-2207.
[10] FRYK J J,MARKS D C,HOBSON-PETERS J,et al.Reduction of Zika virus infectivity in platelet concentrates after treatment with ultraviolet C light and in plasma after treatment with methylene blue and visible light[J].Transfusion,2017,57(11):2677-2682.
[11] FRYK J J,MARKS D C,HOBSON-PETERS J,et al.Deng
ue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light[J].Transfusion,2016,56(9):2278-2285.
[12] RAMSEY G.Hemostatic efficacy of pathogen-inactivated blood components[J].Semin Thromb Hemost,2016,42(2): 172-182.
[13] YANG C H,BIAN G H,YANG H,et al.Quantitative evaluation of plasma after methylene blue and white light treatment in four Chinese blood centers[J].Transfus Apher Sci,2013,49(3):631-639.
[14] GRAVEMANN U,HANDKE W,SUMIAN C,et al.Plasma temperature during methylene blue/light treatment influences virus inactivation capacity and product quality[J].Vox Sang,2018,113(4):368-377.
[15] 钟锐,刘嘉馨,曹晔,等.亚甲蓝光化学法对血浆凝血因子活性的影响研究[J].中国输血杂志,2011,24(1):40-42.
[16] NUBRET K,DELHOUME M,ORSEL I,et al.Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue[J].Transfusion,2011,51(1):125-128.
[17] BOST V,ODENT-MALAURE H,CHAVARIN P,et al.A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France[J].Vox Sang,2013,104(4):337-341.
[18] POLITIS C,KAVALLIEROU L,HANTZIARA S,et al.Haemovigilance data on the use of methylene blue virally inactivated fresh frozen plasma with the Theraflex MB-Plasma System in comparison to quarantine plasma: 11 years' experience[J].Transfus Med,2014,24(5):316-320.
[19] MUÑIZ-DIAZ E,PUIG L.Allergic and anaphylactic reactions to methylene-blue-treated plasma in Catalonia in the period 2008-2013[J].Trasfusione Del Sangue,2014,12(4):628-630.
[20] DEWACHTER P,CASTRO S,NICAISE-ROLAND P,et al.Anaphylactic reaction after methylene blue-treated plasma transfusion[J].Br J Anaesth,2011,106(5):687-689.
[21] AKAZAWA M,WU Y H,LIU W M.Allergy-like reactions to methylene blue following laparoscopic chromopertubation: a systematic review of the literature[J].Eur J Obstet Gynecol Reprod Biol,2019,238:58-62.
[22] 杜斌,陈俊良,唐筛娣,等.亚甲蓝对百草枯中毒大鼠胸腺T淋巴细胞亚群与氧化应激的影响[J].中国病理生理杂志,2016,32(7):1307-1311.
[23] WANG J Q,ZHAO C Y,KONG P,et al.Methylene blue alleviates experimental autoimmune encephalomyelitis by modulating AMPK/SIRT1 signaling pathway and Th17/Treg immune response[J].J Neuroimmunol,2016,299:45-52.
[24] WERNER I,GUO F W,BOGERT N V,et al.Methylene blue modulates transendothelial migration of peripheral blood cells[J].PLoS One,2013,8(12): e82214. DOI:10.1371/journal.pone.0082214.
[25] 姚仁南,陈玲,刘军权,等.病毒灭活血浆对人CIK细胞功能影响的体外实验研究[J].中国输血杂志,2012,25(8): 741-744.
[26] JIANG C L,YANG W Y,WANG C Y,et al.Methylene blue-mediated photodynamic therapy induces macrophage apoptosis via ROS and reduces bone resorption in periodontitis[J].Oxid Med Cell Longev,2019,2019:1529520.
[27] TREVISAN E,MENEGAZZI R,ZABUCCHI G,et al.Effect of methylene blue photodynamic therapy on human neutrophil functional responses[J].J Photochem Photobiol B,2019,199:111605.
[28] JACQUOT C,DELANEY M.Pathogen-inactivated blood products for pediatric patients: blood safety,patient safety,or both?[J].Transfusion,2018,58(9): 2095-2101.
[29] GILLMAN P K.CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity[J].J Psychopharmacol,2011,25(3):429-436.
[30] SCOTTON W J,HILL L J,WILLIAMS A C,et al.Serotonin syndrome: pathophysiology,clinical features,management,and potential future directions[J].Int J Tryptophan Res,2019,12:1178646919873925.
[31] ZUSCHLAG Z D,WARREN M W,K SCHULTZ S.Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome[J].Psychosomatics,2018,59(6):539-546.
[32] AUERBACH S S,BRISTOL D W,PECKHAM J C,et al.Toxicity and carcinogenicity studies of methylene blue trihydrate in F344N rats and B6C3F1 mice[J].Food Chem Toxicol,2010,48(1):169-177.
[33] ARUNACHALAM SUBRAMANIAN N,KRISHNAMOO
RTHY V,KRISHNAN V,et al.An unexplained oxidative haemolysis with pigment nephropathy[J].BMJ Case Rep,2019,12(7):e230994.
[34] VANHINSBERGH L,UTHAYA S,BAIN B J.Methylene blue-induced Heinz body hemolytic Anemia in a premature neonate[J].Am J Hematol,2018,93(5):716-717.
[35] ALLEGAERT K,MISEREZ M,LERUT T,et al.Methemoglobinemia and hemolysis after enteral administration of methylene blue in a preterm infant: relevance for pediatric surgeons[J].J Pediatr Surg,2004,39(1):E35-E37.
[36] JENA S K,NAIK S S.Methemoglobinaemia after diagnostic hystero-laparoscopic chromopertubation in a sub-fertile patient[J].J Obstet Gynaecol,2019,39(7): 1025-1026.
[37] TCHEN S,SULLIVAN J B.Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock[J].J Crit Care,2020,57:148-156.

亚甲蓝光病毒灭活血浆的研究进展^*

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	钟明璐, 黄慧瑛, 张旸, 王立, 汪传喜, 魏亚明. 储存式自体输血在脊柱外科手术中应用的疗效及安全性研究^*[J]. 临床输血与检验, 2021, 23(1): 68-71.
[2]	余凤秀, 李津杞, 朱燕霞, 郭菲, 周载鑫, 顾海慧, 钱宝华. 二次重度离心制备法对冷沉淀凝血因子质量的影响^*[J]. 临床输血与检验, 2020, 22(5): 477-480.
[3]	陈富强, 朱海峰, 肖晨, 李文超, 颜鑫, 刘虹, 李英莲, 陈剑锋, 贺韦东, 王露楠, 李蓬. 新型冠状病毒康复者血浆IgM和IgG不同试剂检测结果的差异分析[J]. 临床输血与检验, 2020, 22(3): 258-263.
[4]	戴永刚. 人凝血因子Ⅸ-V107A-R338A高活性突变体在毕赤酵母中的表达及活性测定[J]. 临床输血与检验, 2019, 21(3): 305-307.
[5]	中国输血协会临床输血管理委员会. 气动管道系统传送血液制剂安全性评估要求^*[J]. 临床输血与检验, 2019, 21(1): 1-2.
[6]	于建, 李兴龙, 杨燕, 钟宁, 李丽玮, 李志强. 气动管道系统对全血血浆凝血因子与生化参数的影响^*[J]. 临床输血与检验, 2019, 21(1): 8-10.
[7]	林建霞, 卓孝福, 江伟梅, 周晓真. ABO血型、性别和年龄对血浆成分中Ⅷ因子和纤维蛋白原含量的影响[J]. 临床输血与检验, 2018, 20(6): 596-600.
[8]	张春鸣,邓金枝,卢素平. 不同贮存温度和不同贮存时间冷沉淀凝血因子Ⅷ含量及合格率变化分析[J]. 临床输血与检验, 2018, 20(4): 396-398.
[9]	杨鹏,闻慧琴,卫玉芝,卞茂红,张循善. 血浆置换在临床危重疾病治疗中的安全性分析*[J]. 临床输血与检验, 2018, 20(3): 242-245.
[10]	李鹏, 郭毅. 亚甲蓝病毒灭活血浆中人细小病毒B19抗原、抗体的检测与分析^*[J]. 临床输血与检验, 2018, 20(1): 20-22.
[11]	曹燕, 曹维娟. 苏州地区临床用血浆中亚甲蓝残留量及安全性调查分析^*[J]. 临床输血与检验, 2017, 19(2): 125-126.
[12]	潘淑敏,郭颖,陈胜,于笑难. 不同方法制备新鲜冰冻血浆对冷沉淀凝血因子质量的影响[J]. 临床输血与检验, 2016, 18(6): 554-556.
[13]	史恩祥, 任爱玲. 血浆输注安全有效性研究进展[J]. 临床输血与检验, 2016, 18(3): 298-301.
[14]	张婵,陈婉璐,程瑜静,李琦,代润,李清. •实验技术与方法•冷沉淀不同融解方式对凝血因子活性的影响*[J]. 临床输血与检验, 2016, 18(2): 146-149.